secwatch.observer — SEC 8-K summary
======================================

Issuer:     LISATA THERAPEUTICS, INC. (LSTA)
CIK:        0000320017
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0000320017-26-000020
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lisata to be acquired by Kuva Labs for $5.00 per share plus contingent $1.00 CVR
--------------------------------------------------------------------------------

- Kuva Labs will acquire all Lisata common shares for $5.00 cash plus one non-tradeable CVR potentially paying $1.00 upon FDA filing for certepetide.
- CVR milestone: payable if NDA is filed/accepted for certepetide within 7 years of closing; Parent must use commercially reasonable efforts.
- Unanimous board recommendation; tender offer with minimum tender condition of majority of outstanding shares (including rollover shares).
- Termination fee of $2M payable by either party under certain circumstances; no financing condition to the offer.
- In-the-money options, restricted stock, and RSUs cashed out at Closing Amount plus CVR; ESPP terminated at closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/320017/000032001726000020/0000320017-26-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/320017/000032001726000020/clbs-20260306.htm
  HTML page:      https://secwatch.observer/filing/0000320017-26-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer